16093393

SAFETY AND EFFECTIVENESS SUMMARY Summit Doppler Systems, Inc.

LifeDop 300ABI

Name and Address:

Summit Doppler Systems, Inc. 4680 Table Mountain Dr. #150

Golden, CO 80403

Phone: (303) 423-7572 Fax: (303) 431-5994

Contact:

Ken Jarrell - President

DEC **2 4** 2009

Preparation Date:

October 23, 2009

Device Name:

LifeDop 300ABI

Common Name:

Peripheral Vascular Doppler

Classification:

Class II per:

FR Number

Product Code

Non-Fetal, Ultrasound Monitor

892.1540

JAF

Indications for Use:

Vascular (5.0 and 8.0 MHz Probes)

This product will be used to detect blood flow in veins and arteries for

assisting in the detection of peripheral vascular disease.

Description:

The LifeDop is a hand-held, battery powered, audio Doppler device used for blood flow detection in veins and arteries. The product includes two interchangeable ultrasound transducer probes and user replaceable batteries. The user interface includes an on/off button, volume control, 12 button keypad for entering pressure data and printing, single 2-1/4" speaker, and LCD display for displaying data, battery and waveform information. The product is housed in custom injection molded housings. Patient contact materials are ABS and Ploycarbonate injection molded plastic and hypoallergenic aqueous gel used for ultrasound transmission.

Substantial Equivalence:

Summit Doppler Systems

Golden, CO

LifeDop Doppler Ultrasound System

K024197, Cleared 1/3/03

Technologies Summary:

Doppler ultrasound technology is the same as substantially equivalent

device shown above. There is no change in the intended use of the device.

Clinical Testing:

None provided

Conclusion:

Based on comparisons of device features, materials, intended use and performance, the LifeDop 300ABI is shown to be substantially equivalent to the commercially available and legally marketed device indicated above.

DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

Mr. Ken Jarrell President Summit Doppler Systems, Inc. 4680 Table Mountain Dr. #150 GOLDEN CO 80403

DEC 2 4 2009

Re: K093393

Trade/Device Name: LifeDop 300ABI Regulation Number: 21 CFR 892.1540

Regulation Name: Nonfetal ultrasonic monitor

Regulatory Class: II Product Code: JAF Dated: October 23, 2009 Received: October 30, 2009

Dear Mr. Jarrell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the LifeDop 300ABI, as described in your premarket notification:

Transducer Model Number

5.0BD MHz CW 8.0BD MHz CW

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

If you have any questions regarding the content of this letter, please contact Shahram Vaezy at (301) 796-6242.

Sincerely yours,

Janine M. Morris

nome to Whay

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure(s)

Attachment C - Indication for Use

Indications for Use

510(k) Number (if known):	X093393
---------------------------	---------

Device Name: LifeDop 300ABI

Indications For Use: This product will be used to detect blood flow in veins and

arteries for assisting in the detection of peripheral vascular

disease.

Prescription Use XPart 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW	/ THIS LINE-CONTI	NUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

Division Sign-Off)

Division of Reproductive, Abdominal,

and Radiological Devices 209393

29

Diagnostic Ultrasound Indications for Use Form

LifeDop 300ABI peripheral vascular system with either 5.0BD MHz CW or 8.0BD MHz CW Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

		Mode of Operation									
Clinical Application	A	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)	
Ophthalmic											
Fetal											
Abdominal											
Intraoperative (specify)											
Intraoperative Neurological											
Pediatric											
Small Organ (specify)											
Neonatal Cephalic											
Adult Cephalic											
Cardiac											
Transesophageal											
Transrectal											
Transvaginal											
Transurethal								<u> </u>			
Intravascular											
Peripheral Vascular					Р						
Laparoscopic			·								
Musculo-skeletal Conventional											
Musculo-skeletal Superficial											
Other (specify)											

Additional Comments:	5.0 MHz Bi-Directional Peripheral Vascular Probe - K063600, 12/19/06
	8.0 MHz Bi-Directional Peripheral Vascular Probe - K063600, 12/19/06
	
(PLE	ASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CRF 801.109)

(Division Sign-Off)

Division of Reproductive, Abdominal,

and Radiological Devices

510(k) Number.

Diagnostic Ultrasound Indications for Use Form

5.0BD MHz CW Peripheral Vascular Probe

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

		_	,	,	Mode of Operation								
Clinical Application	A	В	м	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify			
Ophthalmic													
Fetal													
Abdominal									-				
Intraoperative (specify)	<u> </u>							•					
Intraoperative Neurological									·				
Pediatric	<u> </u>												
Small Organ (specify)													
Neonatal Cephalic													
Adult Cephalic						_							
Cardiac													
Transesophageal													
Transrectal							-	-					
Transvaginal													
Transurethal													
Intravascular													
Peripheral Vascular					P			,					
Laparoscopic													
Musculo-skeletal Conventional													
Musculo-skeletal Superficial													
Other (specify) N= new indication; P= p													

Additional Comments: _	The above is for 5.0 MHz Bi-Directional Peripheral Vascular Probe
	Previously submitted and cleared on K063600, 12/19/06
(PLEA	SE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Pe	er 21 CRF 801 (109)	
	land h	Who -
	(Division Sign-Off)	0
	Division of Reproductive, A	bdominal,

Division of Reproductive, Abdominal, and Radiological Devices

Diagnostic Ultrasound Indications for Use Form

8.0BD MHz CW Peripheral Vascular Probe

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operation									
Clinical Application	Α	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify
Ophthalmic										
Fetal	<u> </u>									
Abdominal	<u> </u>		ļ					·		
Intraoperative (specify)										
Intraoperative Neurological										-
Pediatric										
Small Organ (specify)	_	ļ								
Neonatal Cephalic	<u>.</u>									
Adult Cephalic										
Cardiac						_				
Transesophageal	<u> </u>									
Transrectal										
Transvaginal										
Transurethal										
Intravascular										
Peripheral Vascular					P					
Laparoscopic										
Musculo-skeletal Conventional										
Musculo-skeletal Superficial										
Other (specify)										

Additional Comments:The above is for 8.0 MHz Bi-Directional Peripheral Vascular Probe
Previously submitted and cleared on K063600, 12/19/06
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CRF 801.109)

(Division Sign-Off)
Division of Reproductive, Abdominal, and Radiological Devices

13393